Note: Revenues for privately held companies are statistical evaluations.
Turning Point Therapeutics's annual revenues are $10-$50 million (see exact revenue data) and has 10-100 employees. It is classified as operating in the Medicinal & Botanical Manufacturing industry.
Note: Turning Point Therapeutics's revenues are gauged from an analysis of company filings.
Investor Activity
Turning Point Therapeutics has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
Date
Investors
Percent Raised
Target Size
October 30, 2018
16
100%
$80 MM
Complete list of funding rounds and total amounts in the Company Report
Turning Point Therapeutics's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
Turning Point Therapeutics Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit
Trademark Applications
Trademark applications show the products and services that Turning Point Therapeutics is developing and marketing.
Turning Point Therapeutics doesn't have any recent trademark applications, indicating Turning Point Therapeutics is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
Trademark
Date
TURNING POINT THERAPEUTICS Pharmaceutical preparations for the treatment of cancer
11/21/2018
TP THERAPEUTICS Biochemical research and development; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Pharmaceutical research and development; Research and development in the pharmaceutical and biotechnology fields; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer
01/30/2014
See all trademarks and details in the Full Report.
Recession Risk
Determine whether Turning Point Therapeutics grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Turning Point Therapeutics is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Turning Point Therapeutics's Largest Competitors
A competitive analysis shows these companies are in the same general field as Turning Point Therapeutics, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Turning Point Therapeutics.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
Future Competition: Turning Point Therapeutics's Fastest Growing Competitors
These companies are in the same general field as Turning Point Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.